METHODS: 44 cases were analyzed that are surgically operated with robot-assisted radical prostatectomy performed from February to September in 2016. Preoperative MRI have been conducted for all 44 cases, and the prostate cancer local diagnoses (Region of Interest: ROI) were determined by radiologists using MRI T2 weighed image and Diffusion Weighed Image (DWI), then finally the scores of ADC were calculated. IHC for aSMA, vimentin, CD105, and Tenascin-C (TNC-C) were conducted and classified into three group (none stained, weakly stained, strongly stained) to check the relation of those IHC findings to MRI ADC score before the treatment.
INTRODUCTION AND OBJECTIVES:
The efficacy of various next-generation antiandrogens for CRPC is limited. In this study, we investigated gene expression profiles of CRPC cells with AR knockdown using microarray, and identified candidate drugs for overcoming CRPC through degrading AR splice variants.
METHODS: Three cell lines were used: LNCaP, a human PCa cell line that exhibits androgen-dependent proliferation; C4-2AT6, an androgenindependent CRPC cell line; and 22Rv1 an AR-V7 positive CRPC cell line. Gene expression change by AR knockdown in CRPC cells were analyzed using a microarray and compared using CMAP to identify a candidate drug with the potential to have AR degradation effect similar to AR knockdown. The efficacy of the candidate drug was tested in vitro and in vivo.
RESULTS: We investigated and compared the viability of prostate cancer cells treated with DHT. DHT promoted LNCaP cells proliferation in dose dependent manner. On the other hand, C4-2AT6 cells showed significantly decreased cell viability when treated with DHT. We next perform AR knockdown by SiRNA to LNCaP and C4-2AT6. In WST assay, relative cell viability after AR knockdown was 46.9 % AE 2.7 % and 44.1 AE 2.0 %, respectively. These results suggested that C4-2AT6 depended on AR signaling while it had androgen independence We explored candidate drugs which mimicked AR knockdown to C4-2AT6 by CMAP analysis. We identified a candidate compound for degrading AR in CRPC, AHG113. The cytotoxic effect of AHG113 was investigated by a cell viability assay in LNCaP and C4-2AT6 cells; relative cell viability when treated with 10 mM AHG113 was 79.2 AE 1.1 % and 67.5 AE 1.9 %, respectively. AHG113 was suggested to have higher cytotoxicity to CRPC than androgen dependent PCa (p ¼ 0.002). Western blotting demonstrated AHG113 degrade AR protein in C4-2AT6. Because AR-V7 was focused as a next-generation antiandrogens resistance mechanism, we investigated AR-V7 degradation effect of AHG113. Western blotting and flow cytometry demonstrated AHG113 degraded both AR full length and AR-V7 in 22Rv1. We administered AHG113 to 22Rv1 xenograft mice for investigating anti-tumor effect in vivo. AHG113 significantly inhibited xenograft tumor growth (p < 0.001). Immunohistochemistry of xenograft tumor demonstrated AHG113 reduced AR-V7 expression.
CONCLUSIONS: AHG113 may be promising drug for overcoming androgen-independent and AR-V7 positive CRPC.
INTRODUCTION AND OBJECTIVES: It's accepted that angiogenesis is a complex phenomenon accompanying the development, progression and metastasis of tumors of unrelated histological origin. We introduce the Hurst index to investigate the two-dimensional (2-D) geometrical complexity of the tumor vascular network in biopsy specimens to comprehend whether non-tumoral biopsy cores might be helpful to select patients with hidden prostate cancer.
METHODS: 1984 biopsy cores sampled from a total of 316 patients were analyzed. Patients were categorized in two main groups: a) Prostate Cancer Group: 140 patients with first positive biopsies for prostate cancer and 60 patients negative for prostate cancer at first biopsy and positive at re-biopsy. b) . 199, No. 4S, Supplement, Sunday, May 20, 2018 Control Group: 60 patients negative for prostate cancer at the first, second and third biopsy, and 56 patients with benign prostatic hyperplasia (BPH) following transurethral resection of the prostate (TURP). Two-micrometer thick sections were cut and processed for immunohistochemistry with primary antibodies raised against CD34 (Dako, Milan, Italy). This was followed by 30 min incubation with the Envision system (Dako). 3,3 0 -Diaminobenzidine tetrahydrochloride was used as a chromogen to yield brown reaction products. The histological sections were digitized using a computeraided image analysis system that automatically selected the immunopositive vessels on the basis of RGB color segmentation and calculated the Hurst index by applying the formula: H ¼ Eþ1-D, where the Euclidean dimension E is equal to 1 and D represents the 2-D vascular surface fractal dimension. All of the data were analyzed using Statistica software (StatSoft, Inc., Tulsa, OK, USA) and GraphPad Prism 5 (San Diego, California, USA).
RESULTS: A low Hurst index values in negative core biopsies suggest a higher probability of hidden prostate cancer. We found that Hurst index values in the non-tumoral biopsy below 0.20 suggest that the risk to have hiding prostate cancer is high. In contrast, Hurst indexes in the non-tumoral biopsy upper than 0.35 suggests that the risk to have misunderstood and contemporary prostate cancer is low.
CONCLUSIONS: This study first shows that vascular Hurst index in non-tumoral biopsies might represent a low-cost adjunctive histopathological predictive value of prostate cancer. In addition, the present study first introduces the concept that also the non-tumoral biopsy tissue might have an informative content on the presence of a contemporary cancer.
Source of Funding: none

MP64-08 A NOVEL BIGUANIDE DERIVATIVE DRUG, IM176, INHIBITS PROSTATE CANCER
Choung-Soo KIM, Wonseok Choi*, YOONRIM KIM, Bong-Min Kim, Seoul, Korea, Republic of INTRODUCTION AND OBJECTIVES: Biguanides were originally developed for the treatment of hyperglycemia and type 2 diabetes mellitus. Recently, the biguanides metformin and phenformin have been shown to exert potential anticancer effects in prostate cancer. We evaluated the anti-cancer efficacy and mechanism of IM176, a novel biguanide derivate drug on prostate cancer using prostate cancer cell lines and patient-derived castration-resistant prostate cancer cell lines.
METHODS: Cell viability assay, annexin V-FITC apoptosis detection, microscopy with immunofluorescence staining, real-time quantitative reverse transcription-polymerase chain reaction, and western blotting were conducted. Efficacy of IM176 was also evaluated using 2 cell lines derived from castration-resistant prostate cancer patient.
RESULTS: IM176 dose-dependently inhibited cell viability in all prostate cancer cell lines at lowest IC50 concentrations (LNCaP: 18.5mM, 22Rv1: 36.8 mM) compared to those of metformin, and phenformin. IM176-mediated AMPK activation caused mTOR inhibition, and a decrement in the phosphorylation of p70S6K1 and S6. IM176 inhibited the expression of AR, AR-splice variant 7 (AR-V7) and prostate-specific antigen in LNCaP and 22Rv1. IM176 induced apoptosis with increased levels of cleavage of caspase-3, and annexin V-positive / PI-positive, respectively. Moreover, IM176 inhibited cell viability at lowest IC50 concentrations in 2 cell lines derived from castration-resistant prostate cancer patient. We evaluate the relationship between AMPK-mTOR pathway and AR signaling pathway by blocking each pathway separately. After AR knockdown, phosphorylation of AMPK was significantly increased. However, AR and AR-V7 were not increased after treating AMPK inhibitor, Compound C.
CONCLUSIONS: IM176 showed comparable anti-tumor effects via AMPK-mTOR pathway and AR signaling pathway with the lowest IC50 compared to other biguanide derivative drugs in prostate cancer cell lines, including patient-derived castration resistant prostate cancer cell line and may be a novel anti-cancer drug for the treatment of prostate cancer.
Source of Funding: This study was supported by a grant (W17-686) from Asan Medical Center, Seoul, Korea.
MP64-09 IN SILICO SCREENING USING RNA-SEQ DATA SETS OF NEUROENDOCRINE PROSTATE CANCER HAS IDENTIFIED CANDIDATE DRUGS FOR REPROGRAMMING NEPC-SPECIFIC SIGNATURES.
Takeo Kosaka*, Hiroshi Hongo, Shuji Mikami, Kazuhiro Matsumoto, Eiji Kikuchi, Mototsugu Oya, Tokyo, Japan INTRODUCTION AND OBJECTIVES: Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of castration-resistant prostate cancer (CRPC). The development of effective therapeutic strategies that can achieve improvement in patients with NEPC is urgently needed. In this study, we investigated NGS profiles in NEPC, CRPC or castration sensitive PC to identify candidate drugs with the potential to convert CRPC-NE properties into CRPC-adeno by in silico screenings RNA-seq data.
METHODS: We analyzed RNA-seq data of NEPC and CRPC, and compared using the Broad Institute's Connectivity Map (CMAP) to identify candidate drugs with the potential to revert tumors' NE properties. In drug screening system, we examined cell proliferation for these candidate drugs in human PCa cell lines of CSPC, CRPC, NEPC including LNCaP, C4-2, C4-2AT6, PC3, DU145, NCI-H660. The efficacy was determined in vitro and in vivo by cell viability assay, qPCR, Western Blot, Immunohistochemistry and xenograft tumor bering model.
RESULTS: In silico screening using RNA-seq data sets of NEPC and NCH-H660 allowed us to identify candidate 22 drugs for reprogramming NEPC-specific signatures into CRPC-adeno signatures. Among the listed drugs, we identified THM166 had significantly higher anti-tumor effect in NCI-H660 cells than other cell lines. In NCI-H660, the relative cell viability after treatment with 10 nM or 100 nM THM166 was 71.6 AE 1.2 % and 41.5 AE 0.9 %, respectively. On the other hand, THM166 did not have anti-tumor effect in other CRPC cell lines at the same dose, suggesting the specific selectivility of THM166 for NEPC cells. We investigated the expression of NEPC-related markers of Nmyc, synaptophigin and chromogranin in NCH-H660 cells by qPCR and Western blot (WB) analysis. qPCR and WB analysis revealed THM166 inhibited the expression of NEPC-related markers in a dose dependent manner. We examined the time course changes in NEPC tumor growth using NCI-H660 with THM166. In the controls, the ratio of tumor size on day 10 to day 1 was 192% (p<0.01). In contrast, the ratio of tumor size was 106% in the THM166 monotherapy groups(p<0.01). These results indicate that THM166 has a significant antitumor effect in NCI-H660 in vivo, as well as in vitro.
CONCLUSIONS: We identified a candidate drug: THM166 that can convert NEPC signature in CRPC one through reprograming the Nmyc related transdifferentiation. We propose THM166 as a potential drug for NEPC. . 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e853
